Study Group: Economic Experts on Pharmacy Benefit Management Services

Council Members in this Study Group: 90

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Contact Gerson Lehrman Group to survey or consult with members of this Study Group

Leading institutions connect with members of this Study Group through GLG

Leading Experts in this Study Group

Adam Fein

Founder & President
PEMBROKE CONSULTING INC

Adam Fein, PhD, is the Founder and President of Pembroke Consulting, Inc., a Philadelphia-based management advisory and business research firm. Dr. Fein is one of the country’s foremost experts on pharmacy economics and the pharmaceutical supply chain....

Michael Berman

Assistant Vice President
AON CONSULTING & INSURANCE SERVICES

Michael Berman is the Assistant Vice President at Aon Consulting. He is an experienced group health actuary with over 10 years of broad insurance and consulting experience. Mr. Berman has extensive expertise in the areas of pharmacy, medical, and disability...

Bruce Goldberg

President
Pharmacy Benefit Advisors

Bruce Goldberg is the President of Pharmacy Express Services and Pharmacy Benefit Advisors, both based in Omaha, Nebraska. He is a pharmacist and has experience in managed care with PBM contracting and general pharmacy network management. He developed...

Vikram Singh

Director in Health and Productivity Practice
Buck Consultants, LLC. (Mellon Consultants)

Vikram Singh, MBA, is the Director in the Health and Productivity Practice at Buck Consultants. His expertise is in the financial and business aspects of pharmacy benefit management. Mr. Singh provides strategic advice in the areas of pharmacy benefit...

David Zimmerman

President/Owner
Doctors of Pharmacy, Inc.

David Zimmerman, PharmD, FASCP, is the President and an Independent Consultant of Doctors of Pharmacy. Dr. Zimmerman formerly served as the Director of Clinical Affairs at Employee Health Insurance Management, a pharmacy benefit manager. He has over 30...

View all Leading Experts in this Study Group

GLG News^SM Analyses by this Study Group's Leading Experts (?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Thriving in a time of adversity - Sun Pharma pounces on shortage by getting approval on Oxycodone

April 13, 2009

Analysis by:Aemad Aslam, President,

Analysis of:Sun Pharma gets USFDA's nod to market painkillers | www.hindu.com

Sun Pharma can greatly benefit from the nationwide shortage of Oxycodone Immediate Release Tablet, by getting approval from the FDA on their own generic. With recent recalls from different manufacturers, and the shortage of a comparable product Morphine Sulphate, the FDA currently estimates that return to normal supply levels of Oxycodone may occur in approximately 2 months, during which time Sun Pharma can capitalize on the shortage by securing longer term contracts with wholesalers.

Aurobindo Pharma's Escitalopram will be a big mover ... when it comes out in 2011

March 5, 2009

Analysis by:Aemad Aslam, President,

Analysis of:Aurobindo Pharma receives tentative approval for Escitalopram | www.indiainfoline.com

Forest's Lexapro commands a $2.5+ billion USD market share, just in the US. Due to such a high volume of the brand product, Aurobindo's tentative approval on Lexapro's generic Escitalopram will be a great opportunity - primarily if they can procure a 6 month period of exclusivity from the FDA. Additionally, despite being a brand name product, Lexapro holds an 8%+ year over year increase in the past 3 years. Hence, the market for the drug in September of 2011 when the patent runs out will be closer to a $3 billion market.

Teva's Generic Imitrex commands market of Sumatriptan

February 26, 2009

Analysis by:Aemad Aslam, President,

Analysis of:Teva Announces Approval and Launch of Generic Imitrex(R) Tablets | www.pipelinereview.com

With the 180 day exclusivity, Teva is already commanding the market of the generic Imitrex - Sumatriptan oral tablets. Teva maintains an AB rating of the generic that will render most insurance companies to push brand name Imitrex by GlaxoSmithKline to a non-formulary tier, skyrocketing the generic's sales. Already, different wholesalers are reporting a backorder on Teva's generics. Additionally, Teva's pricing point is very favorable to itself, despite Dr Reddy's prior entrance.

No Visible Revenue Synergies in CVS Caremark's Latest Numbers

February 23, 2009

Analysis by:Adam Fein, Founder & President,

Analysis of:CVS Net Rises; Finance Chief Plans to Retire | online.wsj.com

CVS Caremark’s PBM businesses are not becoming a larger share of prescriptions filled at CVS retail pharmacies. Put another way, the flagship Maintenance Choice program may be appealing to payers and consumers, but there is not yet a quantitatively visible shift in CVS' retail activity. If CVS pharmacies are taking retail pharmacy market share, then it’s not yet as a result of corporate co-ownership with a PBM.

Acquisitions of Indian Pharma on the extended horizon by Brand name pharma

February 23, 2009

Analysis by:Aemad Aslam, President,

Analysis of:Pharma cos on lookout for Indian drug firms | economictimes.indiatimes.com

Acquisitions of various Indian generic pharmaceuticals is likely on the horizon for brand name manufacturers. However, this is not an immediate concern. I would see more consolidations in the US and other Western markets first.

View All GLG News by members of this Study Group

Members in this Study Group include these company types:

Consultancy, Healthcare-Focused
Consultancy, Pharma-Focused
Pharmaceutical Benefits Manager, Large >10 M Lives
Managed Care Health Insurer, For-Profit
Employee Benefits Consulting
Pharmaceutical Benefits Manager, Small <10 M Lives
Healthcare Management
Pharmacy or Drug Store, Chain
Individual/Small Consultancy
Pharmacy or Drug Store, Independent/Local

Members in this Study Group often have these job titles:

Principal
President
Director
Consultant
Operations Executive
Owner
Pharmacist - RPh/PharmD
Chief Executive Officer

Related Study Groups

Study Group Name	No. Members
Economic Experts on Managed Care	714
Generic Drug Economic Experts	766
Managed Care Experts	669
Formulary Design Experts	250
Managed Care Pricing Trends Experts	281
Average Wholesale Pricing Economic Experts: Healthcare Consultants	20
Medicare Experts	493
Employee Benefits Experts	371